Consequently, PRKDC inhibitors were investigated for their potential role in therapy, and they were found to elicit radiosensitizing effects in the D458 cell line, which resembles group 3 medulloblastoma with MYC amplification. This evidence concerns the gene MYC and medulloblastoma.